

CIN: L15142RJ1991PLC006353

SARDA PROTEINS LTD.

Date: 07th November, 2023

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001 (Maharashtra)

(BY BSE LISTING CENTRE)

Sub: Disclosure pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Ref.: Sarda Proteins Ltd, Scrip Code: 519242, Security ID: SRDAPRT.

Dear Sir /Ma'am,

In accordance with Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Un-audited Financial Results of the Company for the quarter and half year ended on 30th September, 2023 along with the Statement of Assets and Liabilities as on 30th September, 2023 and Statement of Cash Flow for the half year ended on 30th September, 2023 and Limited Review Report thereon.

You are requested to kindly take the same on record.

Thanking You,
Yours Faithfully

FOR SARDA PROTEINS LTD

For SARDA PROTEINS LTD

Company Secretary

AMIT KUMAR MODI
COMPANY SECRETARY &
COMPLIANCE OFFICER
M. NO.: A29371

Encl: a/a

Reg. Office: B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan)
Corp. office: Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)
Contact No.: +91-7737822222; **E Mail:** sardaproteins@yahoo.com; **Web:** www.sardaproteins.com



S K AGARWAL & ASSOCIATES

Chartered Accountants

111, 1st Floor, Ganpati Mall, Samtal Road, Bhiwadi-301019 (Raj.)

Mob : 9828115580 | Email : cabhiwadi@gmail.com

Limited Review Report Unaudited Standalone Quarterly Results

To
The Board of Directors
Sarda Proteins Ltd

We have reviewed the accompanying statement of unaudited financial results of **SARDA PROTEINS LTD** for the Quarter and Half Year ended on 30th September, 2023. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S K Agarwal & Associates
Chartered Accountants
FRN: 014841C



CA Sushil Kumar Agarwal
Partner
M. No.: 403073
UDIN : 23403073BGXLAK3585

Place : Jaipur
Date : 07.11.2023

SARDA PROTEINS LTD

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)
Phone: +91 7737822222, EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com
CIN: L15142RJ1991PLC006353

STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30TH SEPTEMBER 2023

Rs. in Lakhs

S. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2023 Un-Audited	30.06.2023 Un-Audited	30.09.2022 Un-Audited	30.09.2023 Un-Audited	30.09.2022 Un-Audited	31.03.2023 Audited
I.	Revenue from Operations	-	23.58	279.21	23.58	279.21	579.52
II.	Other Income	4.13	4.09	2.48	8.22	7.65	15.98
III.	Total Income (I+II)	4.13	27.67	281.69	31.80	286.86	595.50
IV.	Expenses:						
	Cost of Material Consumed	-	-	-	-	-	-
	Purchase of Stock -in- Trade	-	23.63	275.57	23.63	275.57	571.77
	Changes in Inventories (Finished Goods, WIP, Stock-in-Trade)	-	-	-	-	-	-
	Employee Benefit Expenses	2.62	2.74	3.31	5.36	6.75	13.48
	Finance Cost	-	-	-	-	-	-
	Depreciation and Amortisation Expenses	-	-	-	-	-	-
	Other expenses	2.02	1.55	2.54	3.57	4.05	8.96
	Total Expenses (IV)	4.64	27.92	281.42	32.56	286.37	594.21
V.	Profit/(Loss) before Exceptional and Extraordinary Items and Tax (III-IV)	(0.51)	(0.25)	0.27	(0.76)	0.49	1.29
VI.	Exceptional Items	-	-	-	-	-	-
VII.	Profit/(Loss) before Extraordinary Items and Tax (V-VI)	(0.51)	(0.25)	0.27	(0.76)	0.49	1.29
VIII.	Extraordinary Items	-	-	-	-	-	-
IX.	Profit/(Loss) before Tax (V-VI)	(0.51)	(0.25)	0.27	(0.76)	0.49	1.29
X	Tax Expense:						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	-	-	-	-	-	4.60
	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	(0.51)	(0.25)	0.27	(0.76)	0.49	(3.31)
XI	Profit/(Loss) from Discontinued Operations	-	-	-	-	-	-
XII	Tax Expenses of Discontinued Operations	-	-	-	-	-	-
XIII.	Profit/(Loss) from Discontinued Operations (after tax) (X-XI)	-	-	-	-	-	-
XIV.	Profit/(Loss) for the Period (IX+XII)	(0.51)	(0.25)	0.27	(0.76)	0.49	(3.31)
XV	Other Comprehensive Income						
	A (i) Items will not be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	B (i) Items will be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-	-
XVII.	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other Comprehensive Income for the period)	(0.51)	(0.25)	0.27	(0.76)	0.49	(3.31)
	Paid Up Equity Share Capital, Equity Shares of Face Value Rs. 10 each	172.59	172.59	172.59	172.59	172.59	172.59
XVIII	Earnings per Equity Share						
	(1) Basic	(0.03)	(0.01)	0.02	(0.04)	0.03	(0.19)
	(2) Diluted	(0.03)	(0.01)	0.02	(0.04)	0.03	(0.19)

Place: Jaipur

Date : 07-Nov-2023

UDIN: 234030738GK LAR 3585



on behalf of the Board
Sarda Proteins Ltd



Deepak Datta (DIN: 01672415)
Managing Director

SARDA PROTEINS LTD

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)
 Phone: +91 7737822222, EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com
 CIN: L15142RJ1991PLC006353

STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER 2023

Rs in Lakhs

Particulars	Six Months ended		Year ended
	30.09.2023	30.09.2022	31.03.2023
	Un-Audited	Un-Audited	Audited
A. ASSETS			
1. Non-Current Assets			
a) Property, Plant and Equipment			
b) Capital work in progress	0.01	0.01	0.01
c) Investment Property	-	-	-
d) Goodwill	-	-	-
e) Other Intangible Assets	-	-	-
f) Intangible Assets under Development	-	-	-
g) Biological Assets other than bearer plants	-	-	-
h) Financial Assets	-	-	-
i) Investments			
ii) Trade Receivables	0.13	0.13	0.13
iii) Loans	-	-	-
i) Deferred Tax Assets (net)	-	-	-
j) Other non-current Assets	13.49	18.09	13.49
2. Current Assets			
a) Inventories	-	-	-
b) Financial Assets	-	-	-
i) Investments			
ii) Trade Receivables	-	-	-
iii) Cash and Cash Equivalents	-	18.31	-
iv) Bank Balances and other than (iii) above	-	0.25	0.25
v) Loans	6.29	2.51	18.19
v) Others	205.00	205.00	205.00
c) Current Tax Assets (net)	13.00	-	3.38
d) Other Current Assets	-	-	-
Total Assets	-	-	-
	237.92	244.30	240.45
B. EQUITY AND LIABILITIES			
1. Equity			
a) Equity Share Capital			
b) Other Equity	250.45	250.45	250.45
2. Liabilities	(15.86)	(11.31)	(15.10)
Non current Liabilities			
a) Financial Liabilities			
i) Borrowings			
ii) Trade Payables	-	-	-
A) Total Outstanding dues to MSEs	-	-	-
B) Total Outstanding dues to Creditors other than MSEs	-	-	-
iii) Other Financial Liabilities	-	-	-
b) Provisions			
c) Deferred Tax Liabilities (net)	3.24	3.00	2.79
d) Other Non Current Liabilities	-	-	-
Current Liabilities			
a) Financial Liabilities			
i) Borrowings			
ii) Trade Payables	-	-	-
A) Total Outstanding dues to MSEs	-	-	-
B) Total Outstanding dues to Creditors other than MSEs	0.21	1.33	-
iii) Other Financial Liabilities	-	-	-
b) Other Current Liabilities	(0.12)	0.83	2.31
c) Provisions	-	-	-
d) Current Tax Liabilities (net)	-	-	-
Total Equity and Liabilities	237.92	244.30	240.45

Place: Jaipur

Date : 07-Nov-2023

UDIN: 2340307386XLAK3585



on behalf of the Board
Sarda Proteins Ltd

Deepak Datta (DIN: 01672415)
Managing Director

SARDA PROTEINS LTD

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)
 Phone: +91 7737822222, Email: sardaproteins@yahoo.com, website: www.sardaproteins.com
 CIN: L15142RJ1991PLC006353

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER 2023

Rs in Lakhs

Particulars	Six Months ended		Year ended
	30.09.2023	30.09.2022	31.03.2023
	Un-Audited	Un-Audited	Audited
CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit before Tax and Extraordinary Items	(0.76)	0.49	1.29
A. ADJUSTMENT FOR			
Depreciation	-	-	-
Interest Received	(8.22)	(7.65)	(15.98)
Profit on Sale of Investment	-	-	-
Dividend	-	-	-
(Profit) /Loss on sale of Fixed Assets	-	-	-
Interest Paid	-	-	-
Operating Profit/(Loss) before Working Capital Charges	(8.98)	(7.16)	(14.69)
ADJUSTMENT FOR:			
Trade and other Receivables	-	(28.86)	(13.92)
Other Current Assets/ Liabilities	(11.84)	-	-
Inventories	-	-	-
Trade & other Payables	-	(1.45)	(1.51)
Other Non Current Assets/ Liabilities	0.45	-	-
Cash Generated from Operations	(20.37)	(37.47)	(30.12)
Direct Taxes Paid	-	-	-
Net Cash from Operating Activities	(20.37)	(37.47)	(30.12)
B. CASH FLOW FROM INVESTING ACTIVITIES			
Capital Expenditure	-	-	-
Sale of Fixed Assets	-	-	-
Profit/ (Loss) on sale of Fixed Assets	-	-	-
Profit on sale of Investment	-	-	-
Sale of Investment	-	-	-
Interest Received	8.22	7.65	15.98
Dividend Received	-	-	-
Net Cash Received from Investing Activities	8.22	7.65	15.98
C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from Long Term Borrowings	-	-	-
Proceeds from Short Term Borrowings	-	-	-
Interest Paid	-	-	-
Net Cash Inflow/ (Outflow) from Financing Activities	-	-	-
Net Cash Increase/(Decrease) in Cash and Cash Equivalent (A+B+C)	(12.15)	(29.82)	(14.14)
Cash & Cash Equivalent (Opening)	18.44	32.58	32.58
Cash & Cash Equivalent (Closing)	6.29	2.76	18.44


Notes:

1. The above results were approved by Audit Committee and Board of Directors in their meeting held on 07th November, 2023.
2. Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account.
3. Segment Results as per AS is not applicable as dealing in only one segment i.e. "Agro Products".
4. No Investor Complaints were received during the quarter ended 30-Sep-2023 nor any pending as on 01-Oct-2023.
5. Figures for the previous period have been regrouped wherever considered necessary so as to confirm to the classification of the current period.

Place: Jaipur

Date : 07-Nov-2023

UDIN: 23403073BGXLAK3585



on behalf of the Board
Sarda Proteins Ltd

Deepak Data (DIN: 01672415)
Managing Director